Clinical Trial Update: Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of plerixafor and GM-CSF (sargramostim) for mobilizing hematopoietic stem cells from allogeneic sibling donors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• Plerixafor (Mozobil) (plerixafor)
• Sargramostim (Leukine) (sargramostim)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2017-05-03